Clinical trials
Lymphoma, B-Cell clinical trials
Below are recruiting lymphoma, b-cell clinical trials, each written for real people, not researchers. We’re tracking 534 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06241729Recruiting
Observation of first-time DLBCL treatment at Charleroi hospital
This study is watching how people with newly diagnosed diffuse large B cell lymphoma (a blood cancer) are treated for the first time at Grand Hôpital de Charleroi. It collects information to help doctors learn more about the disease and its care.
Charleroi, HainautAges 18 years+ - NCT06249191RecruitingPhase 1/Phase 2
Mosunetuzumab plus chemo for untreated high-grade B-cell lymphoma
This trial tests adding a drug called mosunetuzumab to standard chemotherapy for people with certain aggressive B-cell lymphomas. It aims to see if the combination works better than chemo alone.
Portland, OregonAges 18–75 - NCT06208735RecruitingPhase 1
CLIC-2201 for relapsed or refractory B cell cancers
This trial tests a new treatment called CLIC-2201 for people with certain types of B cell lymphoma or leukemia that have come back or not responded to previous treatments. It aims to see if this therapy can help control the cancer.
Calgary, AlbertaAges 1 year+ - NCT06224309Recruiting
Testing a new imaging tracer for certain blood cancers
This trial tests a new PET/CT imaging tracer called [18F]BL40 to see if it can help spot certain types of blood cancers. It may help doctors better understand and monitor these diseases.
Vancouver, British ColumbiaAges 19–100 - NCT06220032RecruitingPhase 3
Preventing heart damage from chemotherapy in lymphoma
This trial tests if the drug dexrazoxane can protect the heart during chemotherapy for a type of lymphoma called DLBCL. It may be an option for patients starting a standard treatment regimen known as R-CHOP.
's-HertogenboschAges 18 years+ - NCT06209619RecruitingPhase 1
Study of CC-99282 plus rituximab after CAR-T for lymphoma
This trial tests combining an experimental pill (CC-99282) with the immunotherapy drug rituximab for people with B-cell non-Hodgkin's lymphoma whose cancer did not fully respond to CAR-T cell therapy. The goal is to improve results after CAR-T.
Columbus, OhioAges 18 years+ - NCT05780034RecruitingPhase 1
Study drug AC676 for certain relapsed blood cancers
This Phase 1 trial tests AC676, a study medicine, for adults with certain B-cell blood cancers that have come back or did not respond to prior treatment. It may help people who have tried standard therapies and need new options.
Denver, ColoradoAges 18 years+ - NCT06189391RecruitingPhase 1
Testing CN201 for people with relapsed or refractory B-cell lymphoma
This study tests a new drug called CN201 (also known as MK-1045) for people with certain types of B-cell lymphoma that have come back or not responded to previous treatments. The goal is to see if the drug can help shrink or control the cancer.
Beijing, Beijing MunicipalityAges 18–75 - NCT06191887RecruitingPhase 1
BAFFR-targeting CAR-T cells for relapsed B-cell blood cancers
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called BAFFR on B-cell blood cancers. The goal is to see if it can shrink tumors when given after a short chemotherapy course to prepare the body.
Jacksonville, FloridaAges 18 years+ - NCT06173518RecruitingPhase 1
CAR T-cell therapy for children with B-cell leukemia or lymphoma
This trial tests a CAR T-cell therapy that targets CD19 on cancer cells. It is for children whose B-cell acute lymphoblastic leukemia or aggressive B-cell non-Hodgkin lymphoma has come back or not responded to other treatments.
Los Angeles, CaliforniaAges birth–18 years - NCT06156774Recruiting
Sarcopenia and frailty in lymphoma patients getting CAR-T therapy
This trial looks at how muscle loss (sarcopenia) and overall health affect outcomes in people with B-cell lymphoma who are receiving CAR-T cell therapy. It may help doctors better support patients before and after treatment.
AlessandriaAges 18 years+ - NCT06167785RecruitingPhase 2
Study of zanubrutinib and tislelizumab for lymphoma after CAR-T
This trial tests two new drugs (zanubrutinib and tislelizumab) for people with large B-cell lymphoma that has come back or not responded after CAR-T therapy. The goal is to see if these drugs can help when CAR-T hasn't worked.
Toronto, OntarioAges 18 years+ - NCT06176690RecruitingPhase 1
Donor cell therapy for CD30-positive lymphomas
This trial tests a new type of immune cell therapy for CD30-positive lymphomas. The cells are made from donated blood and are designed to find and attack your cancer.
Houston, TexasAges 12–75 - NCT06131801Recruiting
Crushed venetoclax tablet solution study for blood cancers
This study checks how the body handles venetoclax when it's given as a liquid made from crushed tablets. It's for children and young adults with blood cancers who already take venetoclax crushed or through a feeding tube.
Aurora, ColoradoAges birth–38 years - NCT06144606RecruitingPhase 2
KTE-X19 CAR T for MRD+ B-ALL
This trial tests a CAR T-cell therapy called KTE-X19 for people with B-cell ALL that is in remission but still has trace disease (MRD-positive). The goal is to see if this treatment can eliminate the remaining cancer cells and prevent relapse.
Tampa, FloridaAges 18 years+ - NCT06151730Recruiting
Managing blood pressure and heart risks during BTKi treatment
This study looks at how well blood pressure is managed and whether heart problems can be prevented in people with certain blood cancers who are taking a type of targeted therapy called a BTKi. It aims to help you stay healthier during treatment.
Rochester, MinnesotaAges Any age - NCT00626496Recruiting
Family study for certain blood and immune disorders
This study looks at families where more than one close, blood-related person has a lymphoproliferative disorder (a group of conditions where the lymph system makes too many abnormal cells). It aims to better understand why these disorders run in families and how they may be inherited or related.
Rochester, MinnesotaAges 18–100 - NCT06116110Recruiting
Long-term follow-up after gene therapy treatment
This study is a long-term follow-up for people who previously received a gene therapy treatment called zamtocabtagene autoleucel in a Miltenyi Biomedicine-sponsored clinical study. It helps researchers monitor your health over time after the treatment.
Gilbert, ArizonaAges 18 years+ - NCT06104592RecruitingPhase 2
Radiation before CAR T-cell therapy for high-risk large B-cell lymphoma
This trial tests if giving radiation to all visible tumor sites before standard CAR T-cell therapy can improve outcomes for people with high-risk large B-cell lymphoma. You may be eligible if you have at least one large tumor (5 cm or bigger) that can be targeted with radiation.
Tampa, FloridaAges 18 years+ - NCT05890352RecruitingPhase 2
Add new medicines to standard treatment for returning lymphoma
This Phase 2 study tests whether adding tafasitamab, lenalidomide, tazemetostat, and zanubrutinib (along with standard lymphoma treatment) can improve outcomes in people whose large B-cell lymphoma has returned or not responded. It may help control disease more effectively and improve response duration for eligible patients.
Tucson, ArizonaAges 18 years+ - NCT06091865RecruitingPhase 3
Testing odronextamab with chemo for untreated DLBCL
This trial is testing a new drug called odronextamab combined with chemotherapy against the standard treatment for people with previously untreated DLBCL. The goal is to see if the new combination works better and is safe.
Scottsdale, ArizonaAges 18 years+ - NCT03375619Recruiting
Long-term follow-up after CAR-T treatment
This study checks in with people who already received CAR-T therapy to learn how they’re doing over time. It may help doctors understand the long-term benefits and side effects of CAR-T for future patients.
Milwaukee, WisconsinAges 18–80 - NCT05643742RecruitingPhase 1/Phase 2
Study of CTX112 for B-cell cancers that came back or did not respond
This Phase 1/2 study tests how safe and effective CTX112 is for adults whose B-cell cancer has returned or is not responding to treatment. It aims to see whether CTX112 can control the cancer while monitoring side effects closely.
Westwood, KansasAges 18 years+ - NCT06043011Recruiting
Registry for non-Hodgkin lymphoma patients on systemic therapy
This registry tracks people with non-Hodgkin lymphoma who are starting a new line of systemic therapy. It collects information to better understand how treatments work in real life, and optionally asks you to fill out surveys about your symptoms and quality of life.
Freiburg im BreisgauAges 18 years+
Hear when a new Lymphoma, B-Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lymphoma, b-cell?
- Yes. Clin2 currently lists 534 recruiting lymphoma, b-cell studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lymphoma, b-cell trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lymphoma, b-cell trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.